AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 3 - (NewsRx.com & NewsRx.net) -- Antisense to SXR reverses endometrial cell cisplatin resistance.
According to published research from Japan, "a novel steroid and xenobiotic receptor (SXR) may be involved in chemoresistance, and we studied this receptor in endometrial cancer cell lines. The cisplatin (CDDP)-sensitive Ishikawa cell line and its CDDP-resistant sub-clone (ISIW+) were used. ISIW+ cells showed a much higher SXR expression."
"When Ishikawa cells were cultured with SXR anti-sense oligonucleotides (AS), the cells failed to pass crisis and did not gain cisplatin resistance. In an experiment using SCID mice, all AS-treated animals survived, whereas controls had 50% survival at 35 days," wrote N. Takami and colleagues, Nihon University, Department of Obstetrics and Gynecology.
"The present data indicate that SXR is a key system to induce, maintain and reverse a ...
Source: HighBeam Research, Antisense to SXR reverses endometrial cell cisplatin resistance.